Direct-acting vasodilators: Nursing pharmacology

Direct-acting vasodilators: Nursing pharmacology

Watch later

Watch later

Chronic obstructive pulmonary disease (COPD): Nursing process (ADPIE)
Laryngotracheobronchitis (LTB) and croup: Nursing process (ADPIE)
Cellular structure and function
Cell membrane
Selective permeability of the cell membrane
Osmosis
Extracellular matrix
Cytoskeleton and intracellular motility
Cell-cell junctions
Endocytosis and exocytosis
Cell signaling pathways
Resting membrane potential
Cell cycle
Mitosis and meiosis
Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Urinary catheters and routine indwelling catheter care: Clinical skills notes
Sodium homeostasis
Potassium homeostasis
Phosphate, calcium and magnesium homeostasis
Glucocorticoids and mineralocorticoids: Nursing pharmacology
Alpha-1 adrenergic blockers: Nursing pharmacology
Alpha-2 adrenergic agonists: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antiarrhythmics: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Antihyperlipidemics - Statins: Nursing pharmacology
Beta-adrenergic blockers: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Cardiac glycosides: Nursing pharmacology
Direct-acting vasodilators: Nursing pharmacology
Nitrates: Nursing pharmacology
Sympathomimetic medications: Nursing pharmacology
Acid-base map and compensatory mechanisms
Announcing Year of the Zebra in 2023: Educating millions about rare disorders
The Year of the Zebra music video
Adrenal insufficiency: Year of the Zebra
Achalasia: Year of the Zebra
Esophageal atresia and tracheoesophageal fistula: Year of the Zebra
Esophageal cancer: Year of the Zebra
Hirschsprung disease: Year of the Zebra
Anemia of chronic disease: Year of the Zebra
Beta-thalassemia: Year of the Zebra
Hemophilia: Year of the Zebra
Pernicious anemia: Year of the Zebra
Autoimmune polyglandular syndrome type I (NORD): Year of the Zebra
Langerhans cell histiocytosis: Year of the Zebra
Epidermolysis bullosa: Year of the Zebra
Alagille syndrome (NORD): Year of the Zebra
Alkaptonuria: Year of the Zebra
Cornelia de Lange syndrome: Year of the Zebra
Fibromuscular dysplasia: Year of the Zebra
FOXG1 syndrome: Year of the Zebra
Gaucher disease (NORD): Year of the Zebra
Gorlin syndrome: Year of the Zebra
Leprosy: Year of the Zebra
Nail-patella syndrome: Year of the Zebra
PGAP3-congenital disorder of glycosylation: Year of the Zebra
PHACE syndrome: Year of the Zebra
Phenylketonuria (NORD): Year of the Zebra
Pierre Robin sequence: Year of the Zebra
Retroperitoneal fibrosis: Year of the Zebra
Sanfilippo syndrome: Year of the Zebra
Shwachman-Diamond syndrome: Year of the Zebra
Thoracic outlet syndrome: Year of the Zebra
Turner syndrome: Year of the Zebra
Ehlers-Danlos syndrome: Year of the Zebra
Facioscapulohumeral muscular dystrophy: Year of the Zebra
PIK3CA-related overgrowth spectrum (NORD): Year of the Zebra
Reiter syndrome: Year of the Zebra
Brown-Séquard syndrome: Year of the Zebra
Canavan disease: Year of the Zebra
Glioblastoma: Year of the Zebra
Huntington disease: Year of the Zebra
Idiopathic intracranial hypertension: Year of the Zebra
KIF1A-associated neurological disorder: Year of the Zebra
Narcolepsy (NORD): Year of the Zebra
Neuronal ceroid lipofuscinoses (Batten disease): Year of the Zebra
Syringomyelia: Year of the Zebra
Wernicke-Korsakoff syndrome: Year of the Zebra
Buerger disease: Year of the Zebra
Ovarian cancer: Year of the Zebra

Notes

DIRECT-ACTING VASODILATORS
DRUG NAME
hydralazine (Apresoline), minoxidil (Loniten), 
sodium nitroprusside (Nipride, Nitropress) 
*High Alert Medication*
CLASS
Direct-acting vasodilators
MECHANISM OF ACTION
Prevent the increase of intracellular calcium concentration within vascular smooth muscle cells → vasodilation → reduced total peripheral resistance and blood pressure
INDICATIONS
  • Severe refractory hypertension
  • Malignant hypertension
  • Hypertensive emergencies
ROUTE(S) OF ADMINISTRATION
  • Hydralazine: PO, IV, IM
  • Minoxidil: PO
  • Sodium nitroprusside: IV
SIDE EFFECTS
  • Hypotension
  • Dizziness
  • Headache
  • Reflex tachycardia
  • Palpitations
  • Edema
  • Nausea
  • Vomiting
  • GI distress
  • Minoxidil: pericardial effusion (boxed warning), cardiac tamponade
  • Nitroprusside: Cyanide poisoning (boxed warning), hypothyroidism
CONTRAINDICATIONS AND CAUTIONS
  • Cerebrovascular insufficiency
  • Peripheral vascular disease
  • Coronary artery disease
  • Heart failure
  • Mitral valve disease
  • Pregnancy and breastfeeding
  • Septic shock
NURSING CONSIDERATIONS: DIRECT-ACTING VASODILATORS
ASSESSMENT AND MONITORING
Baseline assessment
  • Vital signs, ECG, heart and lung sounds, weight, CBC, electrolytes, hepatic and renal function

Hydralazine IV
  • Patent IV access
  • Frequent vital signs; signs of fluid overload - edema, pulmonary crackles, orthopnea

Nitroprusside IV
  • Continuous cardiorespiratory monitoring
  • Automatic blood pressure monitoring
  • Patent IV access
  • Emergency equipment and sodium thiosulfate readily available
  • Double-check infusion pump settings with a second nurse
  • Monitor for extravasation
  • Assess for signs of toxicity: altered mental status, agitation, tremor
  • For suspected toxicity, stop the infusion and notify the physician immediately; prepare to administer antidote
CLIENT EDUCATION
  • Concurrent use of beta-blocker and diuretic
  • Report signs of water retention, shortness of breath, fast heart beat (reflex tachycardia), chest pain

Hydralazine
  • Take with meals
  • Report side effects: symptoms of lupus-like syndrome: muscle aches, joint pain, fever

Minoxidil
  • Take without regard to meals
  • Can cause reversible increase in hair growth

Nitroprusside
  • Report burning or stinging at IV site, tinnitus
Author: Victoria S. Recalde, MD
Illustrator: Robyn Hughes, MScBMC

Transcript

Watch video only

Direct-acting vasodilators are a class of antihypertensive medications that are used for severe refractory hypertension, malignant hypertension, and hypertensive emergencies. These medications include hydralazine, which can be administered orally, intravenously, and intramuscularly; minoxidil, which can be administered orally or topically; and sodium nitroprusside, which is given intravenously.

Once administered, direct acting vasodilators rapidly work on the vascular smooth muscle cells by preventing the increase of intracellular calcium concentration.

As a result, direct acting vasodilators prevent vasoconstriction and promote vasodilation, leading to a reduction in the total peripheral resistance and blood pressure.

Keep in mind that hydralazine and minoxidil mainly work on arterioles, while sodium nitroprusside works on both arterioles and venules.

Now, since direct acting vasodilators tend to work rapidly, they can result in sudden vasodilation and hypotension. This may lead to side effects, including dizziness, headache, reflex tachycardia, palpitations, and edema.

Other side effects include nausea, vomiting, and gastrointestinal distress. So to counteract side effects like reflex tachycardia and edema, direct acting vasodilators can be used in combination with beta-blockers or diuretics, but under close monitoring for adverse effects.

Now, through an unclear mechanism, hydralazine may trigger a lupus-like syndrome, which can involve multiple organs. Clients may experience severe malaise, myalgia, arthralgia, pericarditis, and hepatosplenomegaly, and upon blood tests, they may present with leukopenia, thrombocytopenia, and positive autoantibodies.

What’s important to keep in mind is that hydralazine-induced lupus-like syndrome mainly affects clients who take higher doses for a prolonged period of time, and can be reversed upon discontinuation of hydralazine.

Regarding minoxidil, an important boxed warning is that it can cause pericardial effusion, which may progress to cardiac tamponade, and it can exacerbate angina pectoris.

On that account, minoxidil should be reserved for hypertensive clients who don’t respond adequately to the maximum therapeutic doses of two other antihypertensive medications and a diuretic.

Another interesting side effect of minoxidil is hypertrichosis, which means excessive hair growth! In fact, minoxidil can be applied topically to promote hair growth and treat hair loss or alopecia.

Finally, sodium nitroprusside has a boxed warning because it contains cyanide, which is released when nitroprusside is metabolized; normally the liver is able to convert the cyanide into a less toxic byproduct called thiocyanate, but if nitroprusside is given over several days, the cyanide can accumulate and cause problems such as disorientation and delirium.

Moreover, if sodium nitroprusside is administered too quickly, clients may develop cyanide poisoning, which can lead to hypoxia and metabolic acidosis.

Cyanide poisoning typically presents with dizziness, confusion, headache, mydriasis, tachypnea, and tachycardia; while severe cases can develop hypotension, apnea, seizures, and even coma.

Finally, sodium nitroprusside can also suppress iodine uptake by thyroid cells, which can lead to hypothyroidism.

Direct-acting vasodilators are contraindicated in clients with cerebrovascular insufficiency and any other condition that could be worsened by a sudden decrease in blood pressure, like peripheral vascular disease, coronary artery disease, heart failure, and mitral valve disease, as well as septic shock.

Sources

  1. "Karch’s Focus on Nursing Pharmacology, 9th edition" LWW (2023)
  2. "Pharmacology: A Patient-Centered Nursing Process Approach, 9th edition" Elsevier Canada (2020)
  3. "Mosby’s 2023 Nursing Drug Reference, 36th edition" Mosby (2022)
  4. "Saunders Comprehensive Review for the NCLEX-RN, 9th Edition" Saunders (2022)
  5. "Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy" Journal of Clinical Medicine (2021)
  6. "Severe Bradycardia Induced by Sofosbuvir and Amiodarone which Resolved after the Discontinuation of Both Drugs" Intern Med (2020)
  7. "Nigella Sativa (Black Seeds), A Potential Herb for the Pharmacotherapeutic Management of Hypertension - A Review" Curr Cardiol Rev (2021)